Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
75% of those who actively prescribe weight loss medications have had patients report side effects (in line with results from Sermo Barometer 31, October 2023 at 77%)
Meanwhile, Umar Razzaq, UK-based pharmacist and co-founder of pharmacyonline.co.uk, noticed a pattern where its the GLP-1 users who are already comfortable with needles that are now branching out into other peptides theyve seen on social media
IV infusion therapy offer personalized options for infusions designed to help you feel better
The question that arises is no longer, "Does it work? But, "Who owns the next generation mechanism? Were likely entering a phase where: Large-cap pharma consolidates metabolic platforms Mid-cap biotech becomes an acquisition target (mechanism-driven) Valuations increasingly reflect mechanism optionality, not single indications And importantly: The winners may not be the first GLP-1 players But those building next-gen metabolic architectures Bottom line: If GLP-1 were the opening trade, multi-pathway metabolic drugs may represent the full cycle
US$ 22.42
US$ 22.08
US$ 23.25
US$ 20.26
US$ 24.78
US$ 22.24
US$ 29.84
US$ 20.23
US$ 21.16
US$ 22.63
US$ 22.23
US$ 29.28
